Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$469.36
4.410.95%
al cierre: -
$469.36
0.000.00%
After hour: 4:00 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Alnylam Pharmaceuticals Inc ha un obiettivo di prezzo di consenso pari a $448.89, stabilito in base alle ultime valutazioni degli analisti di 29. Le ultime 3 valutazioni degli analisti sono state rilasciate da JP Morgan, HC Wainwright & Co. y Morgan Stanley il octubre 13, 2025, octubre 10, 2025 y octubre 6, 2025. Con un obiettivo di prezzo medio di $506 tra le JP Morgan, HC Wainwright & Co. y Morgan Stanley, c'è un implicito 7.81% upside per Alnylam Pharmaceuticals Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
JP Morgan
HC Wainwright & Co.
Morgan Stanley
Stifel
RBC Capital
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Alnylam Pharmaceuticals
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/13/2025 | 0.78% | JP Morgan | $475 → $473 | Maintains | Overweight | |||
10/10/2025 | 21.44% | HC Wainwright & Co. | $570 → $570 | Reiterates | Buy → Buy | |||
10/06/2025 | 1.2% | Morgan Stanley | $405 → $475 | Maintains | Equal-Weight | |||
10/06/2025 | 5.46% | Stifel | $441 → $495 | Maintains | Buy | |||
09/19/2025 | 6.53% | RBC Capital | $435 → $500 | Maintains | Outperform | |||
09/17/2025 | 10.79% | B of A Securities | $453 → $520 | Maintains | Buy | |||
09/16/2025 | 20.59% | Goldman Sachs | $504 → $566 | Maintains | Buy | |||
09/11/2025 | 9.73% | Evercore ISI Group | $280 → $515.05 | Maintains | Outperform | |||
09/08/2025 | 0.14% | BMO Capital | $450 → $470 | Maintains | Outperform | |||
09/02/2025 | 21.44% | HC Wainwright & Co. | $570 → $570 | Reiterates | Buy → Buy | |||
09/02/2025 | 24.21% | Citigroup | $527 → $583 | Maintains | Buy | |||
08/07/2025 | 21.44% | HC Wainwright & Co. | $500 → $570 | Maintains | Buy | |||
08/06/2025 | 1.2% | JP Morgan | $348 → $475 | Maintains | Overweight | |||
08/04/2025 | 4.4% | Oppenheimer | → $490 | Upgrade | Perform → Outperform | |||
08/04/2025 | — | Wolfe Research | — | Upgrade | Underperform → Peer Perform | |||
08/01/2025 | -4.12% | Scotiabank | $342 → $450 | Maintains | Sector Outperform | |||
08/01/2025 | 17.18% | UBS | $403 → $550 | Maintains | Buy | |||
08/01/2025 | -11.58% | Canaccord Genuity | $390 → $415 | Maintains | Buy | |||
08/01/2025 | -15.84% | Wells Fargo | $333 → $395 | Maintains | Equal-Weight | |||
08/01/2025 | -9.66% | Raymond James | $370 → $424 | Reiterates | Outperform → Outperform | |||
08/01/2025 | -1.99% | Barclays | $329 → $460 | Maintains | Overweight | |||
08/01/2025 | -4.34% | Piper Sandler | $304 → $449 | Maintains | Overweight | |||
08/01/2025 | -14.78% | Chardan Capital | $325 → $400 | Maintains | Buy | |||
08/01/2025 | -13.71% | Morgan Stanley | $312 → $405 | Maintains | Equal-Weight | |||
07/31/2025 | 1.84% | Needham | $377 → $478 | Maintains | Buy | |||
07/29/2025 | -21.17% | Raymond James | $308 → $370 | Assumes | Outperform → Outperform | |||
07/21/2025 | -17.97% | Truist Securities | → $385 | Initiates | → Buy | |||
07/16/2025 | -25.86% | JP Morgan | $338 → $348 | Maintains | Overweight | |||
07/11/2025 | -13.93% | Citigroup | $364 → $404 | Maintains | Buy | |||
07/11/2025 | -23.51% | B of A Securities | $336 → $359 | Maintains | Buy | |||
07/07/2025 | -18.19% | Jefferies | $328 → $384 | Maintains | Buy | |||
06/30/2025 | -29.05% | Wells Fargo | $287 → $333 | Maintains | Equal-Weight | |||
06/26/2025 | -19.68% | Needham | $320 → $377 | Maintains | Buy | |||
06/24/2025 | -23.3% | BMO Capital | $300 → $360 | Maintains | Outperform | |||
06/12/2025 | -27.99% | JP Morgan | $330 → $338 | Maintains | Overweight | |||
05/02/2025 | -25.64% | UBS | $331 → $349 | Maintains | Buy | |||
05/02/2025 | -30.76% | Chardan Capital | $300 → $325 | Maintains | Buy | |||
04/11/2025 | -42.9% | Morgan Stanley | $284 → $268 | Maintains | Equal-Weight | |||
04/09/2025 | -31.82% | Needham | $320 → $320 | Reiterates | Buy → Buy | |||
04/02/2025 | 6.53% | HC Wainwright & Co. | $500 → $500 | Reiterates | Buy → Buy | |||
03/31/2025 | -27.13% | Scotiabank | $338 → $342 | Maintains | Sector Outperform | |||
03/31/2025 | -24.79% | Redburn Atlantic | → $353 | Initiates | → Buy | |||
03/31/2025 | -26.5% | Stifel | $300 → $345 | Maintains | Buy | |||
03/24/2025 | -30.12% | JP Morgan | $280 → $328 | Upgrade | Neutral → Overweight | |||
03/21/2025 | -25.22% | Citigroup | $338 → $351 | Maintains | Buy | |||
03/21/2025 | -16.91% | Canaccord Genuity | $385 → $390 | Maintains | Buy | |||
03/21/2025 | -29.69% | RBC Capital | $310 → $330 | Maintains | Outperform | |||
03/21/2025 | -27.99% | Scotiabank | $300 → $338 | Maintains | Sector Outperform | |||
03/21/2025 | -38.85% | Wells Fargo | $275 → $287 | Maintains | Equal-Weight | |||
03/21/2025 | -30.76% | B of A Securities | $302 → $325 | Maintains | Buy | |||
03/21/2025 | -36.08% | Chardan Capital | $300 → $300 | Maintains | Buy | |||
03/21/2025 | -31.82% | Needham | $320 → $320 | Reiterates | Buy → Buy | |||
03/11/2025 | -40.34% | JP Morgan | $272 → $280 | Maintains | Neutral | |||
02/26/2025 | -33.95% | RBC Capital | $310 → $310 | Reiterates | Outperform → Outperform | |||
02/26/2025 | -36.08% | Chardan Capital | $300 → $300 | Maintains | Buy | |||
02/26/2025 | -31.82% | Needham | $320 → $320 | Reiterates | Buy → Buy | |||
02/25/2025 | 6.53% | HC Wainwright & Co. | $400 → $500 | Reiterates | Buy → Buy | |||
02/24/2025 | 6.53% | HC Wainwright & Co. | $400 → $500 | Maintains | Buy | |||
02/18/2025 | -17.97% | Canaccord Genuity | $384 → $385 | Maintains | Buy | |||
02/14/2025 | -36.08% | Scotiabank | $310 → $300 | Maintains | Sector Outperform | |||
02/14/2025 | -39.49% | Morgan Stanley | $275 → $284 | Maintains | Equal-Weight | |||
02/14/2025 | -31.82% | Needham | $320 → $320 | Reiterates | Buy → Buy | |||
02/11/2025 | -36.08% | RBC Capital | $300 → $300 | Reiterates | Outperform → Outperform | |||
01/21/2025 | -36.08% | RBC Capital | $300 → $300 | Reiterates | Outperform → Outperform | |||
01/13/2025 | -14.78% | HC Wainwright & Co. | $400 → $400 | Reiterates | Buy → Buy | |||
01/13/2025 | -31.82% | Needham | $320 → $320 | Reiterates | Buy → Buy | |||
01/07/2025 | -33.95% | Bernstein | $314 → $310 | Maintains | Outperform | |||
11/18/2024 | -36.94% | Piper Sandler | $296 → $296 | Reiterates | Overweight → Overweight | |||
11/18/2024 | -14.78% | HC Wainwright & Co. | $400 → $400 | Reiterates | Buy → Buy | |||
11/12/2024 | — | Wolfe Research | — | Downgrade | Peer Perform → Underperform | |||
11/04/2024 | -14.78% | HC Wainwright & Co. | $400 → $400 | Reiterates | Buy → Buy | |||
11/01/2024 | -36.51% | Raymond James | $275 → $298 | Maintains | Outperform | |||
11/01/2024 | -36.08% | RBC Capital | $300 → $300 | Reiterates | Outperform → Outperform | |||
11/01/2024 | -33.95% | Scotiabank | $305 → $310 | Maintains | Sector Outperform | |||
11/01/2024 | -29.9% | Barclays | $295 → $329 | Maintains | Overweight | |||
11/01/2024 | -18.19% | Canaccord Genuity | $366 → $384 | Maintains | Buy | |||
11/01/2024 | -36.08% | Chardan Capital | $300 → $300 | Maintains | Buy | |||
11/01/2024 | -31.82% | Needham | $320 → $320 | Reiterates | Buy → Buy | |||
10/21/2024 | -20.96% | TD Cowen | $282 → $371 | Maintains | Buy | |||
10/18/2024 | -14.78% | HC Wainwright & Co. | $400 → $400 | Reiterates | Buy → Buy | |||
10/16/2024 | -35.02% | Scotiabank | → $305 | Initiates | → Sector Outperform | |||
10/14/2024 | -33.1% | B of A Securities | $307 → $314 | Maintains | Buy | |||
10/11/2024 | -36.08% | Chardan Capital | $300 → $300 | Maintains | Buy | |||
10/11/2024 | -53.13% | Cantor Fitzgerald | $220 → $220 | Reiterates | Neutral → Neutral | |||
10/10/2024 | -36.08% | RBC Capital | $300 → $300 | Reiterates | Outperform → Outperform | |||
10/10/2024 | -31.82% | Needham | $320 → $320 | Reiterates | Buy → Buy | |||
09/19/2024 | -36.08% | RBC Capital | $300 → $300 | Reiterates | Outperform → Outperform | |||
09/09/2024 | -53.13% | Cantor Fitzgerald | $220 → $220 | Reiterates | Neutral → Neutral | |||
09/04/2024 | -36.08% | RBC Capital | $300 → $300 | Reiterates | Outperform → Outperform | |||
09/04/2024 | -34.59% | B of A Securities | $295 → $307 | Maintains | Buy | |||
08/30/2024 | -14.78% | HC Wainwright & Co. | $400 → $400 | Reiterates | Buy → Buy | |||
08/26/2024 | -40.34% | JP Morgan | $248 → $280 | Maintains | Neutral | |||
08/20/2024 | -14.78% | HC Wainwright & Co. | $400 → $400 | Reiterates | Buy → Buy | |||
08/16/2024 | -21.17% | Goldman Sachs | $198 → $370 | Upgrade | Neutral → Buy | |||
08/02/2024 | -36.08% | RBC Capital | $265 → $300 | Maintains | Outperform | |||
08/02/2024 | -50.36% | Wells Fargo | $207 → $233 | Maintains | Equal-Weight | |||
08/02/2024 | -41.41% | Raymond James | $242 → $275 | Maintains | Outperform | |||
08/02/2024 | -57.81% | Goldman Sachs | $174 → $198 | Maintains | Neutral | |||
08/02/2024 | -27.13% | Citigroup | $291 → $342 | Maintains | Buy | |||
08/02/2024 | -37.15% | Barclays | $291 → $295 | Maintains | Overweight |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Alnylam Pharmaceuticals (ALNY)?
El último precio objetivo de Alnylam Pharmaceuticals (NASDAQ:ALNY) fue comunicado por JP Morgan el octubre 13, 2025. La firma de analistas fijó un precio objetivo para $473.00 que espera ALNY a rise dentro de 12 meses (un posible 0.78% upside). 81 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Alnylam Pharmaceuticals (ALNY)?
La última calificación de analistas para Alnylam Pharmaceuticals (NASDAQ:ALNY) fue proporcionada por JP Morgan, y Alnylam Pharmaceuticals mantuvo su overweight calificación.
¿Cuándo se produjo la última revisión al alza de Alnylam Pharmaceuticals (ALNY)?
La última revisión al alza de Alnylam Pharmaceuticals Inc se produjo en agosto 4, 2025, cuando Oppenheimer elevó su precio objetivo a $490. Oppenheimer anteriormente tenía a perform para Alnylam Pharmaceuticals Inc.
¿Cuándo fue la última revisión a la baja de Alnylam Pharmaceuticals (ALNY)?
La última revisión a la baja de Alnylam Pharmaceuticals Inc se produjo en noviembre 12, 2024, cuando Wolfe Research cambió su precio objetivo de N/A a N/A para Alnylam Pharmaceuticals Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Alnylam Pharmaceuticals (ALNY)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Alnylam Pharmaceuticals, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Alnylam Pharmaceuticals se registró el octubre 13, 2025, por lo que la próxima calificación estará disponible en torno al octubre 13, 2026.
¿Es correcta la calificación de los analistas sobre Alnylam Pharmaceuticals (ALNY)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Alnylam Pharmaceuticals (ALNY) fue un mantuvo con un precio objetivo de $475.00 a $473.00. El precio actual al que cotiza Alnylam Pharmaceuticals (ALNY) es de $469.36, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.